EUCTR2006-003561-13-GB进行中（未招募）1 期
Reversal of steroid insensitivity in COPD by theophylline
imperial college0 个研究点目标入组 30 人开始时间: 2012年1月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants with COPD with an FEV1 of 80-30% predicted.
- •This will incorporate the majority of participants with COPD seen within the chest clinic. Patients with an FEV1 > 80% predicted are not generally severe enough to warrant hospital follow up. These patients are also unlikely to have severe enough disease (and therefore airway inflammation) which may be modified by the therapeutic agents we are studying.
- •Patients with an FEV1 < 30% tend to have more severe symptom limitation and generally (though not always) find participation in a clinical trial involving 4 visits to the clinic difficult. Their airway disease is also generally less responsive to therapeutic intervention and as a consequence finding measurements which show changes to these therapeutic interventions is more difficult.
- •COPD patients
- •· All participants will be classified to Stage 2-3 of the GOLD (Global initiative for Obstructive Lung Disease) guidelines.
- •· Male or female, aged 45–80 years (according to GOLD guidelines)
- •· 30% < FEV1 < 80% predicted
- •· FEV1/FVC < 70%
- •· Cigarette exposure of >10 pack-years#
- •· With or without chronic symptoms (cough, sputum production, dyspnea).
- •· Steroid therapy will be stopped before run-in, but long acting bronchodilators are acceptable.
- •· The participants are able to give informed consent
- •# The smoking history should include both the number smoked, for how long, and an estimate of total pack-years of smoking. One pack of 20 cigarettes smoked per day for 1 year = one pack year.
- •Total pack years = No. cigarettes smoked per day/20 x no. years of smoking
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any history or evidence of asthma
- •· Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator
- •· Hospital admission with respiratory infection within the last 6 months
- •· Upper respiratory infection within the last 4 weeks
- •· Participants who have received research medication within the previous one month
- •· Participants unable to give informed consent
- •· Any mental condition rendering the participent unable to understand the nature, scope and possible consequences of the study
- •· Known or suspected hypersensitivity to study therapy or excipients
- •· Participants with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled
- •hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator
- •· Any current respiratory tract disorders other than COPD, which is considered by the investigator to be clinically significant
- •· Any significant disease or disorder (e.g. gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
- •malignant, psychiatric, major physical impairment) or abnormality laboratory tests which, in the opinion of the investigator,
- •may either put the participent at risk because of inclusion in the study, or may influence the results of the study, or the participants ability to take part in the study.
研究者
相似试验
招募中
1 期
COPD - Eosinophil-guided Reduction of Inhaled Corticosteroids (COPERNICOS)Chronic obstructive pulmonary disease (COPD)CTIS2022-501035-16-01Gentofte Hospital444
进行中（未招募）
1 期
The effect of reduced corticosteroid therapy in patients with acute exacerbation of COPD1) Whether a reduction of the dose systemic corticosteroids (SC) therapy in patients with acute exacerbation of COPD(AE-COPD) - compared with AE-COPD patients in the standard treatment- leading to non-inferiority 2)Whether there is a difference in treatment response in AE-COPD patients with eosinophilic airway inflammation compared to AE-COPD patients with non-eosinophilic airway inflammation 3) whether a lower accumulated dose SC may be associated with fewer corticosteroid adverse eventsMedDRA version: 20.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855EUCTR2015-003441-26-DKChronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)320
已完成
4 期
Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPDChronic Obstructive Pulmonary DiseaseNCT02209974Hospital Son Llatzer23
进行中（未招募）
1 期
Clinical trial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic azithromycin therapy in patients with severe or very severe chronic obstructive pulmonary disease (COPD)Clinicaltrial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic azithromycin therapy in patients with severe or very severe chronic obstructive pulmonary disease (COPD)MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2020-003014-12-DKChronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)444
招募中
1 期
Effect of Corton on olfactory dysfunction in COVID-19 patientsAnosmiaIRCT20200522047542N1Mashhad University of Medical Sciences70